
Opinion|Videos|February 9, 2026
Barriers to Managing Alzheimer Disease
Author(s)Ken Cohen, MD, FACP
Panelists discuss how APPs help overcome social and systemic barriers to Alzheimer care.
Advertisement
Episodes in this series

Panelists discuss how social, financial, and systemic challenges hinder Alzheimer management. Limited access to specialists, diagnostic costs, and caregiver burnout are recurring themes.
Panelists discuss how APPs advocate for patients by navigating insurance processes, connecting families with resources, and promoting equitable access to care regardless of socioeconomic status.
Panelists discuss how addressing these barriers requires policy awareness and community outreach. APPs’ holistic approach positions them as champions of accessible, patient-centered care.
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.

Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.
Advertisement
Advertisement
Trending on AJMC
1
Emerging Threats to Cell and Gene Therapy Access
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
4
Tirzepatide Lowers BMI by 18.5% in Adolescents With Obesity
5

